Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy.

Cancer medicine - 1 Dec 2024

Satake Tomoyuki, Morizane Chigusa, Okada Mao, Nishioka Mariko, Hiraoka Nobuyoshi, Nara Satoshi, Kakegawa Tomoya, Kobayashi Maki, Koyama Kumiko, Esaki Minoru, Okusaka Takuji

Abstract excerpt

BACKGROUND: Although activation of human epidermal growth factor receptor 3 (HER3) is linked to resistance to targeted therapies in several cancer types, the HER3 expression profile during pancreatic cancer treatment remains unknown. AIMS: We evaluated the HER3 expression status after chemotherapy for pancreatic cancer and its association with clinicopathological features and clinical outcomes. MATERIALS &...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Biomarkers, Tumor

Share to Immunohistochemistry

Share to Pancreatic Neoplasms

Share to Receptor, ErbB-3

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39651731
DOI: 10.1002/cam4.70474
PMCID: PMC11626478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy.PMID 39651731Read ↗

ITGA3 serves as a diagnostic and prognostic biomarker for pancreatic cancerSemantic proximity Read ↗

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsSemantic proximity Read ↗

Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells.Semantic proximity Read ↗

Understanding the biology of HER3 receptor as a therapeutic target in human cancerSemantic proximity Read ↗

Pan‐cancer analysis of TIM ‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneitySemantic proximity Read ↗

HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of CancerSemantic proximity Read ↗

Integrated bioinformatics analysis shows integrin alpha 3 is a prognostic biomarker for pancreatic cancerSemantic proximity Read ↗

Regulation of ERBB3/HER3 signaling in cancer.Semantic proximity Read ↗

HER3/ErbB3, an emerging cancer therapeutic target.Semantic proximity Read ↗

Molecular Pathways: HER3 Targeted TherapySemantic proximity Read ↗

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapySemantic proximity Read ↗

HER3 Expression and PIK3CA Mutational Status Predict Pathological Response of Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.